Drug profile

The FDA adverse-event record for Phenylpropenolamine

Name: Phenylpropenolamine - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

14 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Phenylpropenolamine. See the species affected, top reactions, and outcomes below.

14
adverse-event reports: 35.7%
death-coded share: Dog
most-reported species: 3
Hind limb paresis - top reaction

Compiled by PlainBreed Editorial, Pet Health Editorial Team

Verify with FDA CVM →

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

35.7%

Death Rate

Active Ingredients

Phenylpropenolamine

Administration Routes

UnknownOral

Species Affected

Dog 14

Most Affected Breeds

Retriever - Labrador 5

Sheepdog - Shetland 2

Shepherd Dog - Australian 2

Weimaraner 2

Black Mouth Cur 1

Coonhound - Bluetick 1

Terrier - West Highland White 1

Most Reported Reactions

Hind limb paresis 3

Death by euthanasia 3

Diarrhoea 3

Mental confusion 2

Dull 2

Skin sore 2

Paraparesis 2

Limb weakness 2

Anorexia 2

Lethargy (see also Central nervous system depression in Neurological) 2

Death 2

Partial lack of efficacy 2

Outcome Breakdown

Ongoing

6 (42.9%)

Euthanized

3 (21.4%)

Died

2 (14.3%)

Recovered/Normal

2 (14.3%)

Outcome Unknown

1 (7.1%)

Phenylpropenolamine Adverse Event Insights

14 reports name Phenylpropenolamine; 5 recorded a death outcome (35.7% of reported events, not a population-level mortality rate). Active ingredient: Phenylpropenolamine. Administration routes: Unknown, Oral.

By species: Dog (14 reports). By breed: Retriever - Labrador (5), Sheepdog - Shetland (2), Shepherd Dog - Australian (2).

Leading clinical signs: Hind limb paresis (3), Death by euthanasia (3), Diarrhoea (3), Mental confusion (2). Outcome, 14 coded reports: Ongoing leads at 42.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.